Floatz logo

Gemcabene

Familial Partial Lipodystrophy

Elif OralPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Familial Partial Lipodystrophy cohort.

Asset / SponsorPhaseRating
R-Methuleptin
University of Michigan
Phase 2B
VUPANORSEN
Akcea Therapeutics
Phase 2B

Same molecule, other indications

Gemcabene is also rated in:

hypertriglyceridemiaDormant
CCC
Indicative ·
52 / 100
View asset →
metabolic dysfunction-associated steatotic liver diseaseDormant
CCC
Indicative ·
51 / 100
View asset →
metabolic dysfunction-associated steatohepatitisDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →